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Introduction 
Polycystic Ovarian Syndrome (PCOS) is the 
most common endocrine disorder 
affecting women of reproductive age, with 
a reported incidence rate of six to twenty 
percent in the United States (Witchel et 
al., 2019). 
PCOS affects women of every ethnic and 
socioeconomic background. If untreated, 
PCOS can lead to chronic and debilitating 
diseases. 
It is essential that advance practice nurses 
(APN) understand how this disease 
process affects women’s health and 
provide early intervention to prevent 
chronic disease. 
Topic Selection 
The prevalence of PCOS is rising and is a 
disease process that significantly impacts 
women’s health throughout their lifespan. 
This project aims to facilitate education 
among APNs to understand the unique 
disease pathophysiology of PCOS and to 
identify solutions that promote health and 
well-being for women. 
Implications for the 
Advance Practice 
Nurse 
Early identification, treatment, and 
prevention of comorbidities is essential; 
however, many primary care providers 
miss the opportunity to diagnose PCOS 
during routine visits. Strikingly, it is 
estimated that as many as seventy-five 
percent of patients remain undiagnosed 
after visiting their primary care provider 
(Wolf et al., 2018). 
The development of PCOS comorbidities 
such as type II diabetes results in high 
healthcare costs and poor community 
health outcomes (Ding et al., 2018). 
There is a unique opportunity for APNs 
working in family practice to identify 
PCOS, provide early interventions, 
educate on lifestyle changes to promote 
health and decrease chronic disease 
(Pfieffer, 2019). 
Signs & Symptoms 
PCOS is a cluster of symptoms. Each patient presentation is different based on the 
underlying disease mechanism. The four cardinal signs of the disease are 
hyperandrogenism, menstruation irregularities, polycystic ovarian morphology, and 
metabolic disorders (Osibogun et al., 2020). 
The following are common signs and symptoms which are grouped according to disease 
mechanism. 
Hyperandrogenism 
• Hirsutism (Ashraf et al., 2019) 
• Acne (Ashraf et al., 2019) 
• Androgenic alopecia (Ashraf et al., 2019) 
Polycystic ovarian morphology 
• Infertility (McCance & Huether, 2019) 
• Pregnancy complications (McCance & Huether, 2019) 
Menstruation irregularities 
• Menorrhagia (Papadakis et al., 2019) 
• Anovulation (Papadakis et al., 2019) 
Figure 1. Polycystic ovarian morphology as seen on ultrasound. 
Retrieved from 
https://medpix.nlm.nih.gov/search?allen=true&allt=true&alli=true&qu 
ery=Polycystic%20ovarian. Reprinted with permission as per 
https://medpix.nlm.nih.gov/licensing 
Conclusion 
PCOS presents as a complex and evolving cluster of symptoms. More research is 
needed to identify the pathophysiology pathway and to develop effective 
pharmacological treatments. 
Recognizing how PCOS alters neuroendocrine signaling, metabolic function, and 
ovarian health is essential to providing appropriate treatment interventions. 
Increasing screening for PCOS during routine health visits can help effectively treat 
PCOS symptoms and reduce chronic illness 
APNs should implement a multifactorial approach to successful treatment of PCOS 
throughout women's lifespan. 
Underlying Pathophysiology 
PCOS is a multifactorial disease process with both genetic and environmental etiology. 
A multifactorial genetic inheritance and lifestyle factors may influence the disease 
phenotype expressed throughout the patient’s lifespan (Ashraf et al., 2019). There is a 
strong genetic link in the disease expression, with the prevalence of PCOS increasing 
55-60% with a first degree relative with the disease (Khan et al., 2019). 
Neuroendocrine, metabolic, and ovarian dysfunction contribute to disfunction in the 
signaling pathways, resulting in a cycle that progresses the disease state. 
The primary systemic dysfunction of PCOS is a hyperandrogenic state. Excess androgen 
secretion by the ovarian stroma promotes follicular ovarian growth resulting in an 
abnormal number of ovarian follicles (McCance & Huether, 2019). 
Disordered gonadotropin secretion of luteinizing hormone (LH) and decreased follicle 
stimulating hormone increases ovarian follicle growth resulting in disrupted 
menstruation cycles (McCance & Huether, 2019). 
The hyperandrogenic state contributes to a defect in the insulin molecular signaling 
pathway (Witchel et al., 2019). Excess insulin suppresses apoptosis and promotes 
follicle development in the ovaries (McCance & Huether, 2019). Excess insulin 
contributes to weight gain and metabolic disorders, which further perpetuate the 
hyperandrogenic state (Witchel et al., 2019). 
Increased androgen suppresses the ovulation cycle leading to ovarian hyperplasia 
(Witchel et al., 2019). 
Figure 2 Disrupted neuroendocrine signaling, metabolic and ovarian dysfunction 
create a cycle which perpetuates the disease state. 
Retrieved July 30, 2021 from 
https://doi.org/10.3389/fcell.2021.639704. US National Library of Medicine. 
Reprinted with permission as per 
https://www.ncbi.nlm.nih.gov/pmc/about/copyright/ 
Significance of Pathophysiology 
Given the cyclical nature of the disease process, women 
with PCOS are at an increased risk for developing chronic 
disease. 
Metabolic syndrome, perpetuated by a hyper-insulin state 
can contribute to the development of obesity, insulin 
resistance, Type II diabetes, hyperlipidemia, hypertension, 
cardiovascular disease (Osibogun et al., 2020). 
Inhibition of follicular development contributes to 
estrogen dominance and hyperplasia of the endometrial 
lining (McCance & Huether, 2019). Women with PCOS are 
three times more likely to develop endometrial carcinoma 
than women with normal menstruation cycles (McCance 
& Huether, 2019). 
PCOS is a cluster of syndromes with variable clinical 
presentations. It is essential for the APN to recognize the 
unique pathophysiology that contributes to these 
symptoms and provide a patient-centered, holistic care 
plan. 
Nursing Care 
Identify PCOS during routine visits. Due to genetic 
link, each patient visit should include an in-depth 
history and physical. Any female patient presenting 
with symptoms related to hyperandrogenism, irregular 
menstrual cycles, or metabolic syndrome should have 
further diagnostic testing (Witchel et al., 2019). 
Early interventions. For adolescences, PCOS can 
promote the development of obesity, acne, and 
hirsutism which can negatively impact social and 
psychological development (Pfieffer, 2019). Screening 
for pre-pubescent female patients is crucial to 
preventing disease progression (Witchel et al., 2019). 
Target treatment to pathophysiological 
dysfunction. Providers should approach women’s 
health problems with attention to how female 
pathophysiology uniquely contributes to the disease 
state. The primary therapeutic goal in the treatment of 
PCOS is aimed at reducing hyperandrogenism. First-
line treatment includes estrogen/progestin 
combination oral contraceptives disease (Lim & 
Hutchison et al., 2019). 
Educate on lifestyle changes. Weight reduction 
through lifestyle changes, including diet modification 
and exercise, reduces the risk of developing metabolic 
disorders and type II diabetes. Weight reduction 
reduces hyperinsulinemia, improves insulin sensitivity, 
and decreases hyperandrogenism (Ding et al., 2018). 
Support patient holistic wellbeing. PCOS symptoms 
can negatively impact women’s mental and emotional 
wellbeing (Lim et al., 2019). FNPs can support patient’s 
health outcomes by implementing holistic lifespan 
care that supports the physical and psychological 
wellbeing of PCOS patients (Lim et al., 2019). 
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